Geron completes stem cell sale to BioTime subsidiary
This article was originally published in Scrip
Executive Summary
It's been almost two years since Geron ended its human embryonic stem cell programs and 11 months since the firm agreed to sell its stem cell assets to BioTime, and the companies finally completed their all-stock transaction on 1 October.